


SUBSTITUTE FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE CITATION		ATTY. DOCKET NO. 08321-0185US1	SERIAL NO. 09/832,424
		APPLICANT: CROCE et al.	
		FILING DATE April 11, 2001	GROUP 1632

U.S. PATENT DOCUMENTS


EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE (IF APPROPRIATE)

FOREIGN PATENT DOCUMENTS

		DOCUMENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

<i>rw</i>	A	FONG LOUISE Y Y et al., "Muir-Torre-like syndrome in Fhit-deficient mice", <i>Proceedings of the National Academy of Sciences of USA, National Academy of Science</i> (25 April 2000), pages 4742-4747.
<i>iw</i>	B	DUMON KRISTOFFEL R et al., "FHIT gene therapy prevents tumor development in Fhit-deficient mice", <i>Proceedings of the National Academy of Sciences of USA, National Academy of Science</i> (13 March 2001), pages 3346-3351.
<i>ww</i>	C	JI LIN et al., "Induction of apoptosis and inhibition of tumorigenicity and tumor growth by adenovirus vector-mediated fragile histidine triad (FHIT) gene overexpression", <i>Cancer Research, American Association for Cancer Research</i> (15 July 1999); vol. 59, no. 14, pages 3333-3339.
<i>ww</i>	D	CROCE C M et al., "Role of Fhit in Human Cancer", <i>Journal of Clinical Oncology</i> (5 May 1999); vol. 17, no. 5, pages 1618-1624.

EXAMINER 	DATE CONSIDERED 1-18-05
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	